Another landmark prospective phase 3 trial involving anti-PD-1 therapy was Checkmate-238, which looked at 906 patients with Stage IIIB-IV completely resected melanoma who were treated with either nivolumab or ipilimumab [31]. This evidence concerns the gene PDCD1 and melanoma.